Comparative Pharmacology
Head-to-head clinical analysis: KAPVAY versus LUMIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAPVAY versus LUMIFY.
KAPVAY vs LUMIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and blood pressure.
Selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness.
0.1 mg orally twice daily, may increase by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day in divided doses.
Instill 1 drop in the affected eye(s) every 6 to 8 hours as needed, not to exceed 4 drops per eye per day.
None Documented
None Documented
Terminal elimination half-life 12-16 hours (range 6-24 h) in adults; prolonged in renal impairment (up to 41 h) and in neonates.
Approximately 2.5-3 hours (terminal) in adults; clinical context: duration of mydriasis may be shorter than half-life due to receptor binding.
Renal: 40-60% unchanged; fecal: minimal (<10%); biliary: negligible.
Primarily renal (60-70% unchanged), with biliary/fecal elimination accounting for the remainder.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist